GlycoMimetics, Inc. (GLYC)

1.6200 -0.1800 (-10.00%) At close: 04:00PM EDT

GlycoMimetics, Inc.

9708 Medical Center Drive
Rockville, MD 20850
United States
240 243 1201
https://www.glycomimetics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 35

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Harout Semerjian	CEO, President & Director	1.13M	N/A	1970
Ms. Rachel K. King	Co-Founder & Director	40k	N/A	1959
Mr. Brian M. Hahn	Senior VP & CFO	822.12k	N/A	1974
Dr. Edwin Rock M.D., Ph.D.	Senior VP & Chief Medical Officer	677.4k	N/A	1961
Ms. Stephanie R. Irish CPA	Vice President of Accounting	N/A	N/A	1971
Mr. Christian B. Dinneen-Long	General Counsel & Company Secretary	N/A	N/A	N/A
Mr. Bruce Johnson	Senior VP & Chief Commercial Officer	N/A	N/A	1968
Mr. Chinmaya Rath	Senior VP & Chief Business Officer	N/A	N/A	1977
Mr. Shantha Tyavanagimatt Ph.D.	Senior Vice President of Technical Operations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Corporate governance

GlycoMimetics, Inc.’s ISS governance QualityScore as of 29 April 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.